Chatbot Monitoring for Lung Cancer Medication Adherence
(iSMART Trial)

Recruiting in Palo Alto (17 mi)

Overseen bySamuel U Takvorian, MD, MSHP

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: University of Pennsylvania

No Placebo Group

Trial Summary

What is the purpose of this trial?

The objective of this project is to identify effective strategies to help patients with lung cancer manage side effects and achieve optimal adherence to oral targeted therapies. To achieve this objective, we will evaluate the effect of a novel, bidirectional conversational agent, compared to usual care, on adherence to oral targeted therapies using a two-arm randomized controlled trial, and explore how multilevel factors impact the acceptability and effectiveness of this strategy by collecting qualitative and quantitative data from clinicians and patients.

Research Team

Katharine A Rendle, PhD,MSW,MPH

Principal Investigator

University of Pennsylvania

Samuel U Takvorian, MD, MSHP

Principal Investigator

University of Pennsylvania

Eligibility Criteria

This trial is for adults over 18 with non-small cell lung cancer (NSCLC) at UPHS who are taking specific oral therapies and own a mobile device that can text. They must be able to interact in English and have their oncologist's approval to participate, but cannot be in another therapeutic clinical trial or taking multiple oral therapies.

Inclusion Criteria

Approval from the patient's medical oncologist to be approached

Ability to provide informed consent to participate in the study

Ability to respond to questions and engage with "Penny" in English

See 2 more

Exclusion Criteria

I cannot communicate or understand English well enough to use 'Penny'.

You cannot use text messaging on your phone.

Concurrent enrollment in a therapeutic clinical trial

See 3 more

Treatment Details

Interventions

Conversational Agent/Chatbot (Behavioural Intervention)
Usual Care (Behavioural Intervention)

Trial OverviewThe study compares usual care against the use of a conversational agent/chatbot named 'Penny' designed to help patients manage side effects and stick to their medication schedule. It's a two-arm randomized controlled trial where participants will either continue with their regular care or engage with 'Penny'.

Participant Groups

2Treatment groups

Experimental Treatment

Active Control

Group I: Intervention ArmExperimental Treatment1 Intervention

Participants in the intervention arm will be tracked and able to engage with the intervention (conversational agent) on their mobile telephone for 12 weeks.

Group II: Control ArmActive Control1 Intervention

Patients in the control arm will receive usual care, which includes clinician-driven education on medication management and self-monitoring of symptoms.